RemeGen (9995) Stock Overview
A biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
9995 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
RemeGen Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$76.90 |
| 52 Week High | HK$126.60 |
| 52 Week Low | HK$15.50 |
| Beta | 0.72 |
| 1 Month Change | -5.35% |
| 3 Month Change | -12.96% |
| 1 Year Change | 329.61% |
| 3 Year Change | 58.88% |
| 5 Year Change | -25.34% |
| Change since IPO | 10.17% |
Recent News & Updates
Recent updates
Subdued Growth No Barrier To RemeGen Co., Ltd. (HKG:9995) With Shares Advancing 27%
Jan 13
RemeGen Co., Ltd.'s (HKG:9995) Intrinsic Value Is Potentially 38% Above Its Share Price
Jan 03What RemeGen Co., Ltd.'s (HKG:9995) 32% Share Price Gain Is Not Telling You
Sep 18Need To Know: Analysts Are Much More Bullish On RemeGen Co., Ltd. (HKG:9995) Revenues
Aug 27RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 26% But Its Business Is Yet to Catch Up
Jul 29RemeGen Co., Ltd.'s (HKG:9995) 28% Price Boost Is Out Of Tune With Revenues
Jun 10RemeGen (HKG:9995) Is Carrying A Fair Bit Of Debt
May 12RemeGen Co., Ltd.'s (HKG:9995) 68% Price Boost Is Out Of Tune With Revenues
Apr 21RemeGen Co., Ltd.'s (HKG:9995) Shares Bounce 33% But Its Business Still Trails The Industry
Mar 06Shareholder Returns
| 9995 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -2.3% | -12.7% | -4.0% |
| 1Y | 329.6% | 51.5% | 15.5% |
Return vs Industry: 9995 exceeded the Hong Kong Biotechs industry which returned 51.5% over the past year.
Return vs Market: 9995 exceeded the Hong Kong Market which returned 15.5% over the past year.
Price Volatility
| 9995 volatility | |
|---|---|
| 9995 Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.4% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 9995 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9995's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3,070 | Jianmin Fang | www.remegen.com |
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors.
RemeGen Co., Ltd. Fundamentals Summary
| 9995 fundamental statistics | |
|---|---|
| Market cap | HK$52.91b |
| Earnings (TTM) | HK$804.08m |
| Revenue (TTM) | HK$3.69b |
Is 9995 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9995 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.25b |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥3.25b |
| Other Expenses | CN¥2.54b |
| Earnings | CN¥708.52m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Mar 28, 2026
| Earnings per share (EPS) | 1.27 |
| Gross Margin | 100.00% |
| Net Profit Margin | 21.79% |
| Debt/Equity Ratio | 94.1% |
How did 9995 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/05 22:34 |
| End of Day Share Price | 2026/03/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RemeGen Co., Ltd. is covered by 30 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |
| Ziyu He | China International Capital Corporation Limited |